Central City

Researchers are evaluating a health services research intervention called the Quality Implementation of Lung Cancer Screening QUILS System, aimed at improving lung cancer screening programs across Kentucky. The study focuses on optimizing statewide lung cancer screening to reduce late-stage lung cancer diagnoses, especially in high-risk areas like Kentuckys Central Appalachian region. This effort is motivated by data showing that lung cancer screening implementation in Kentucky has already contributed to a faster decline in late-stage diagnoses compared to the national average. The intervention involves lung cancer screening program teams receiving the QUILS System, which includes completing the QUILS Index Assessment, participating in QUILS Audit and Feedback presentations, accessing the QUILS Resource Portal, and developing site-specific action plans. Participants also engage in formative evaluation interviews to support the implementation process. This approach is designed to integrate best practices and quality improvement elements into existing screening programs. Participants, who are members or administrators of lung cancer screening programs, will be involved in surveys, audit feedback sessions, and interviews over the course of the study. Researchers will assess changes in the QUILS Index Assessment scores from baseline to month 9 to measure improvements in lung cancer screening quality. The study spans from April 2025 to June 2028, aiming to enhance screening effectiveness and reduce lung cancer burden through program quality improvements.

Researchers are working to improve lung cancer screening programs through an optimization pathway called the QUILS System. This initiative involves assessing current screening programs to identify elements that enhance quality and patient retention. The study focuses on delivering feedback reports to help programs prioritize improvements for better lung cancer screening outcomes. The study uses the QUILS System, which includes statewide coalition engagement through surveys, interviews, educational outreach, and collaborative activities. These efforts aim to raise awareness, improve coordination, support policy, and promote equitable and high-quality lung cancer screening programs. Participants in the study include physicians, nurses, administrators, and other staff involved in lung cancer screening programs. They will engage in the QUILS Index Assessment Survey, receive audit feedback presentations, and participate in formative evaluation interviews. The primary outcome is the change in the QUILS Index Assessment Score one year after the study start. The overall study period extends until June 2028.

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Researchers are evaluating the study drug sacituzumab govitecan SG Trodelvy GS-0132 IMMU 132 compared to standard of care SOC treatments in participants who have previously been treated for extensive stage small cell lung cancer ES-SCLC. The main goal is to compare how SG versus SOC affects overall survival OS in this population. This is a global, multicenter, randomized, open-label, phase 3 clinical trial focusing on treatment outcomes for ES-SCLC. Participants are randomly assigned to one of two groups. Treatment Group A receives sacituzumab govitecan intravenously at 10 mgkg on Days 1 and 8 of a 21-day cycle, continuing until disease progression, death, unacceptable toxicity, or other reasons for stopping treatment. Treatment Group B receives investigator-selected standard care options within a 21-day cycle, including topotecan given daily on Days 1 through 5, lurbinectedin as an intravenous infusion on Day 1 where approved, or in Japan, amrubicin daily on Days 1 through 3. Treatment continues under the same conditions as Group A. Participants will undergo regular assessments including imaging scans to measure disease status, laboratory tests, and monitoring for side effects. Researchers will evaluate overall survival for up to 4.5 years and secondary outcomes such as progression-free survival, response rates, duration of response, and effects on symptoms like shortness of breath and physical functioning. Safety will be tracked through adverse event reporting and laboratory abnormalities throughout the study duration.

Researchers are evaluating participants with cancer in a non-interventional, multicenter, multicohort study to observe plasma circulating tumor DNA ctDNA biomarker changes over time. This study aims to gather valuable data alongside participants standard cancer treatments to better understand cancer biology. The study is sponsored by Tempus AI and focuses on various cancer types including KRAS mutated colorectal, pancreatic, and lung cancers, gastric cancer, metastatic prostate cancer, and others. Participants in this observational study will not receive any study interventions or treatments. Instead, they will provide blood samples at specific time points throughout their treatment journey for ctDNA analysis and other molecular studies. The study includes multiple cohorts representing different cancer types, but no additional therapies are assigned by the study team. During the study, participants will undergo regular blood draws to monitor ctDNA levels at baseline, during treatment, and after treatment for up to five years. Researchers will also generate DNA, RNA, immune, and other molecular datasets from these samples. The study involves no experimental treatments, focusing on data collection to support future cancer research. Participation may last up to five years, with ongoing monitoring of biomarker changes and data generation.